Get startedLog in
    Picture of Intercept Pharmaceuticals logo

    ICPT — Intercept Pharmaceuticals News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMid CapHigh Flyer
    All News

    Brief: Intercept, Unit Enters Into Agreement With Optimus Pharma, Optimus Drugs

    Picture of Intercept Pharmaceuticals logoIntercept Pharmaceuticals
    17/01/2023 15:20
    Jan 17 (Reuters) - Intercept Pharmaceuticals Inc
 ICPT.O :
    * INTERCEPT PHARMACEUTICALS -  ON JAN 14, CO AND UNIT
ENTERED INTO
A SETTLEMENT AGREEMENT WITH OPTIMUS PHARMA PVT. LTD. AND OPTIMUS
DRUGS PRIVATE LTD.
    * INTERCEPT- GRANTED OPTIMUS NON-EXCLUSIVE, ROYALTY-FREE
LICENSE
TO COMMERCIALIZE GENERIC VERSION OF OCALIVA IN U.S. FROM APRIL
26, 2034, OR EARLIER

Further company coverage:  ICPT.O 
 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Intercept Pharmaceuticals

    See all news